XCSport体育
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
XCSport体育:Products in R&D
Clinical Trial
Science & Technology
R&D Result
XCSport体育:Innovation Centre
XCSport体育:Technology Platform
Quality Management
XCSport体育:Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
XCSport体育:Financial Reports
XCSport体育:Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
Multi-media
Media Reports
XCSport体育:Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
XCSport体育:Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
XCSport体育:Marketed Products
XCSport体育:Products in R&D
Clinical Trial
XCSport体育:Science & Technology
XCSport体育:R&D Result
XCSport体育:Innovation Centre
XCSport体育:Technology Platform
XCSport体育:Quality Management
XCSport体育:Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
XCSport体育:Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
XCSport体育:Contact Information
Customer Message
Privacy
XCSport体育:Legal Statement
Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
XCSport体育:Popular Science
Highlights
Download
XCSport体育:Media Reports
Media Enquiry
2026-01-26
Results from Clinical Trials of Two Henlius’ Innovative Products Released at ASCO GI 2025
2026-01-24
Serplulimab plus HLX04 for HCC: Phase 2 Results Published in Cancer Immunology, Immunotherapy
2026-01-13
Henlius Broadens Access to Multiple Biologics in Emerging Markets
2026-01-09
Henlius to Present Latest Clinical Data of HLX10 and HLX22 at 2025 ASCO GI
2026-01-06
Henlius Receives the NMPA IND Approval for Its PD-L1-Targeting ADC HLX43 in Combination with Novel Anti-PD-1 mAb Serplulimab
1
...
4
5
6
7